Articles | Volume 8, issue 6
https://doi.org/10.5194/jbji-8-219-2023
https://doi.org/10.5194/jbji-8-219-2023
Original full-length article
 | 
30 Oct 2023
Original full-length article |  | 30 Oct 2023

Antimicrobial prophylaxis with teicoplanin plus gentamicin in primary total joint arthroplasty

Tariq Azamgarhi, Craig Gerrand, John A. Skinner, Alexander Sell, Robert A. McCulloch, and Simon Warren

Viewed

Total article views: 665 (including HTML, PDF, and XML)
HTML PDF XML Total BibTeX EndNote
493 119 53 665 41 38
  • HTML: 493
  • PDF: 119
  • XML: 53
  • Total: 665
  • BibTeX: 41
  • EndNote: 38
Views and downloads (calculated since 30 Oct 2023)
Cumulative views and downloads (calculated since 30 Oct 2023)

Viewed (geographical distribution)

Total article views: 643 (including HTML, PDF, and XML) Thereof 643 with geography defined and 0 with unknown origin.
Country # Views %
  • 1
1
 
 
 
 
Latest update: 12 Jul 2024
Download
Short summary
We compared prosthetic joint infection (PJI) and acute kidney injury (AKI) rates among cohorts before and after changing our hospital's antimicrobial prophylaxis from cefuroxime to teicoplanin plus gentamicin for primary total joint arthroplasty. Switching to teicoplanin and gentamicin was associated with a significant risk reduction for PJI of 75.2 %. Significantly higher AKI rates were seen in patients receiving teicoplanin plus gentamicin; however, these were mild (KDIGO stage 1).